CLINICAL TRIALS PROFILE FOR MIRICORILANT
✉ Email this page to a colleague
Clinical Trials for Miricorilant
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT03818256 ↗ | This Phase 2, Double Blind, Placebo-controlled, Randomized Study is to Assess the Safety and Efficacy of Miricorilant in Obese Adult With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications. | Recruiting | Corcept Therapeutics | Phase 2 | This phase 2, double blind, placebo-controlled, randomized study is to assess the safety and efficacy of miricorilant in obese adult with schizophrenia treated with antipsychotic medications. |
| NCT03823703 ↗ | Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH) | Terminated | Corcept Therapeutics | Phase 2 | This phase 2, double blind, placebo-controlled, randomized study is to assess the safety and efficacy of miricorilant (CORT118335) in patients with presumed Nonalcoholic Steatohepatitis (NASH). |
| NCT04524403 ↗ | Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II) | Recruiting | Corcept Therapeutics | Phase 2 | This Phase 2, double-blind, placebo-controlled, randomized study is to assess the safety and efficacy of miricorilant (CORT118335) in obese patients with schizophrenia treated with antipsychotic medications. |
| NCT04672499 ↗ | Single and Multiple Dose Study of Miricorilant (CORT118335) Tablet Formulations in Healthy Participants | Completed | Corcept Therapeutics | Phase 1 | This study will assess the safety, tolerability, and pharmacokinetics (PK) of miricorilant (CORT118335) tablet formulations following single and multiple oral administration in healthy participants. |
| NCT05117489 ↗ | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH) | Recruiting | Corcept Therapeutics | Phase 1 | This phase 1b, Open-Label Study is to assess the safety, efficacy of miricorilant in patients with presumed Nonalcoholic Steatohepatitis (NASH) |
| NCT05553470 ↗ | Phase 1 Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant | Not yet recruiting | Corcept Therapeutics | Phase 1 | The primary objective of this study is to determine the effect of hepatic impairment on the pharmacokinetics (PK) of miricorilant following a single oral dose by comparing participants with normal hepatic function with participants with moderate hepatic impairment with or without nonalcoholic steatohepatitis (NASH). |
| NCT05712265 ↗ | Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant | Recruiting | Corcept Therapeutics | Phase 1 | The primary objective of this study is to evaluate the pharmacokinetics (PK) of miricorilant in the presence and absence of the strong cytochrome P450 [(CYP) 2C19] inhibitor, fluvoxamine, in healthy participants. Participants will receive a single dose of miricorilant under fed conditions with a standard breakfast after an overnight fast alone and in combination with once-daily doses of fluvoxamine. Blood samples will be collected at regular intervals for PK and safety analysis between admission and discharge from the clinical unit. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Miricorilant
Condition Name
| Condition Name for | |
| Intervention | Trials |
| Antipsychotic-induced Weight Gain (AIWG) | 2 |
| Nonalcoholic Steatohepatitis (NASH) | 2 |
| Antipsychotic Induced Weight Gain, Non-alcoholic Steatohepatitis (NASH) | 1 |
| Healthy | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for Miricorilant
Trials by Country
Clinical Trial Progress for Miricorilant
Clinical Trial Phase
Clinical Trial Sponsors for Miricorilant
Sponsor Name
